×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
中南大学 [1]
内容类型
期刊论文 [1]
发表日期
2015 [1]
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共1条,第1-1条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
发表日期升序
发表日期降序
作者升序
作者降序
提交时间升序
提交时间降序
题名升序
题名降序
Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review
期刊论文
Drug Design, Development and Therapy, 2015, 卷号: 9, 页码: 5277-5285
作者:
Huang, Ruixue
;
Ding, Ping
;
Yang, Fei*
收藏
  |  
浏览/下载:15/0
  |  
提交时间:2019/12/03
CDH1
as a tumor suppressor gene
contributes sporadic breast cancer (BC) progression. However
the association between CDH1 hypermethylation and BC
and its clinicopathological significance remains unclear. We conducted a meta-analysis to investigate the relationship between the CDH1 methylation profile and the major clinicopathological features. A detailed literature was searched through the electronic databases PubMed
Web of Science™
and EMBASE™ for related research publications. The data were extracted and assessed by two reviewers independently. Odds ratios (ORs) with corresponding confidence intervals (CIs) were calculated and summarized respectively. The frequency of CDH1 methylation was significantly higher in invasive ductal carcinoma than in normal breast tissues (OR =5.83
95% CI 3.76–9.03
P<0.00001). CDH1 hypermethylation was significantly higher in estrogen receptor (ER)-negative BC than in ER-positive BC (OR =0.62
95% CI 0.43–0.87
P=0.007). In addition
we found that the CDH1 was significantly methylated in HER2-negative BC than in HER2-positive BC (OR =0.26
95% CI 0.15–0.44
P<0.00001). However
CDH1 methylation frequency was not associated with progesterone receptor (PR) status
or with grades
stages
or lymph node metastasis of BC patients. Our results indicate that CDH1 hypermethylation is a potential novel drug target for developing personalized therapy. CDH1 hypermethylation is strongly associated with ER-negative and HER2-negative BC
respectively
suggesting CDH1 methylation status could contribute to the development of novel therapeutic approaches for the treatment of ER-negative or HER2-negative BC with aggressive tumor biology.
©版权所有 ©2017 CSpace - Powered by
CSpace